A study of an experimental drug for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pulmonary arterial hypertension (PAH) by a doctor.
- Your PAH causes some limitation in physical activity, such as feeling tired or short of breath during daily activities (WHO functional class II or III).
- You are already on stable treatment for PAH and your doses have not changed recently.
- You can walk between 150 and 550 meters in 6 minutes, measured twice during screening.
- You do not have other types of pulmonary hypertension caused by heart or lung disease, blood clots, or other conditions.
- You have not had any bleeding in your brain or increased pressure in your head in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.